Increased Expression and Activity of the Transcription Factor FOXO1 in Nonalcoholic Steatohepatitis

Valenti, Luca; Rametta, Raffaela; Dongiovanni, Paola; Maggioni, Marco; Fracanzani, Anna Ludovica; Zappa, Marco; Lattuada, Enzo; Roviaro, Giancarlo; Fargion, Silvia
May 2008
Diabetes;May2008, Vol. 57 Issue 5, p1355
Academic Journal
OBJECTIVE--Nonalcoholic fatty liver, affecting 34% of the U.S. population, is characterized by hepatic insulin resistance, which is more marked in the presence of steatohepatitis, and frequently precedes hyperglycemia. The molecular mechanisms underlying the relationship between fatty liver and insulin resistance are still undergoing definition and have not been evaluated in humans. Our aim was to evaluate the relationship between insulin resistance and the expression and regulation of forkhead box-containing protein O subfamily-1 (FOXO1), a transcription factor that mediates the effect of insulin on the gluconeogenic genes PEPCK and glucose-6-phosphatase catalytic subunit (G6PC). RESEARCH DESIGN AND METHODS--FOXO1, PEPCK, and G6PC mRNA levels were evaluated in 84 subjects: 26 with steatohepatitis, 28 with steatosis alone, 14 with normal liver histology without metabolic alterations, and 16 with hepatitis C virus chronic hepatitis, of Whom 8 were with and 8 were without steatosis. Protein expression and regulation of FOXO1 and upstream insulin signaling were analyzed in a subset. RESULTS--Expression of PEPCK was higher in steatohepatitis compared with steatosis alone and normal liver, and it was correlated with the homeostasis model assessment of insulin resistance (HOMA-IR) index. FOXO1 mRNA levels were higher in steatohepatitis, correlated with PEPCK and G6PC mRNA and with HOMA-IR. FOXO1 upregulation was confirmed at protein levels in steatohepatitis and, in the presence of oxidative stress, was associated with decreased Ser[sup 256] phosphorylation, decreased Akt1, and increased Jun NH[sub 2]-terminal kinase-1 activity. Consistently, immunohistochemistry showed increased FOXO1 expression and nuclear localization in steatohepatitis. FOXO1 mRNA levels correlated with nonalcoholic steatohepatitis activity score and were modulated by drugs counteracting hepatic lipogenesis. CONCLUSIONS--FOXO1 expression and activity are increased in patients with steatohepatitis, and mRNA levels are correlated with hepatic insulin resistance. Diabetes 57:1355-1362, 2008


Related Articles

  • Role of Transcription Factor Modifications in the Pathogenesis of Insulin Resistance. Mi-Young Kim; Jin-Sik Bae; Tae-Hyun Kim; Joo-Man Park; Yong Ho Ahn // Experimental Diabetes Research;2012, Special section p1 

    Non-alcoholic fatty liver disease (NAFLD) is characterized by fat accumulation in the liver not due to alcohol abuse. NAFLD is accompanied by variety of symptoms related to metabolic syndrome. Although the metabolic link between NAFLD and insulin resistance is not fully understood, it is clear...

  • Approach to the Pathogenesis and Treatment of Nonalcoholic Steatohepatitis. Medina, Jesús; Fernández-Salazar, Luis I.; García-Buey, Luisa; Moreno-Otero, Ricardo // Diabetes Care;Aug2004, Vol. 27 Issue 8, p2057 

    Nonalcoholic steatohepatitis (NASH) represents an advanced stage of fatty liver disease developed in the absence of alcohol abuse. Its increasing prevalence in western countries, the diagnostic difficulties by noninvasive tests, and the possibility of progression to advanced fibrosis and even...

  • Metabolic Syndrome Is Associated with Greater Histologic Severity, Higher Carbohydrate, and Lower Fat Diet in Patients with NAFLD. Kang, Hellan; Greenson, Joel K.; Omo, Jason T.; Chao, Cewin; Peterman, Debra; Anderson, Lilian; Foess-Wood, Laura; Sherbondy, Mary A.; Conjeevaram, Hari S. // American Journal of Gastroenterology;Oct2006, Vol. 101 Issue 10, p2247 

    OBJECTIVES: Nonalcoholic fatty liver disease (NAFLD) is considered as the hepatic manifestation of metabolic syndrome. Insulin resistance (IR) is a key component of metabolic syndrome. The aim was to determine the dietary composition, physical activity, and histologic severity between NAFLD...

  • Impact of Steatosis on Insulin Secretion in Chronic Hepatitis C Patients. Narita, Ryoichi; Abe, Shintaro; Tabaru, Akinari; Otsuki, Makoto // American Journal of Gastroenterology;Oct2007, Vol. 102 Issue 10, p2173 

    OBJECTIVES: Liver steatosis is frequently observed in patients with chronic hepatitis C (CHC) and is an identified risk factor for progression of liver fibrosis. This study aimed to evaluate the relationship between steatosis and host/viral factors, and the correlation between steatosis and...

  • Dietary Manipulation Alters the Phenotype of NAFLD in a Mouse Model - Implications for Human NASH. Subramanian, Savitha; Yeh, Matthew M.; Kowdley, Kris V.; Chait, Alan // Diabetes;Jun2007 Supplement 1, Vol. 56, pA456 

    Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome. A "two-hit" hypothesis has been proposed for progression of a normal healthy liver to steatohepatitis (NASH), involving first the development of obesity and insulin resistance (IR) followed by...

  • Esteatosis hepática, esteatohepatitis y marcadores de lesión hepática. Barba Evia, José Roberto // Revista Mexicana de Patologia Clinica;oct-dic2008, Vol. 55 Issue 4, p216 

    Nonalcohlic fatty liver disease affects a large proportion of the population. Is a clinicopathological entity characterized by the development of histological changes in the liver that are nearly identical to those induced by excessive alcohol intake, but in the absence of intake of this....

  • The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). Qing Liu; Stig Bengmark; Shen Qu // Lipids in Health & Disease;2010, Vol. 9, p42 

    Nonalcoholic fatty liver disease is increasingly regarded as a hepatic manifestation of metabolic syndrome, and the severity of nonalcoholic fatty liver disease seems to increase in parallel with other features of metabolic syndrome. Excess lipid accumulation in the liver cells is not only a...

  • The Fatty Liver and Insulin Resistance. Yki-Järvinen, H.; Westerbacka, J. // Current Molecular Medicine;May2005, Vol. 5 Issue 3, p287 

    Obesity is not necessary to observe insulin resistance in humans since severe insulin resistance also characterizes patients lacking subcutaneous fat such as those with HAART (highlyactive antiretroviral therapy) - associated lipodystrophy. Both the obese and the lipodystrophic patients have,...

  • The blind men 'see' the elephant-the many faces of fatty liver disease. Sanal, Madhusudana Girija; Hübscher, Stefan G. // World Journal of Gastroenterology;2/14/2008, Vol. 14 Issue 6, p831 

    Nonalcoholic fatty liver disease (NAFLD) is a group of diseases with excess fat in liver in the absence of a poorly defined limit of alcohol consumption. Most common variety, a universal public health problem, is associated with insulin resistance caused by a host of genetic and epigenetic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics